In a screen of drugs previously tested in humans we identified itraconazole, a systemic antifungal, as a potent antagonist of the Hedgehog (Hh) signaling pathway that acts by a mechanism distinct from its inhibitory effect on fungal sterol biosynthesis. Systemically administered itraconazole, like other Hh pathway antagonists, can suppress Hh pathway activity and the growth of medulloblastoma in a mouse allograft model and does so at serum levels comparable to those in patients undergoing antifungal therapy. Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.
INTRODUCTION
The Hh signaling pathway is critical for embryonic growth and patterning in organisms ranging from insects to mammals (Varjosalo and Taipale, 2008) . Hh signaling also functions postembryonically in tissue homeostasis through effects on stem or progenitor cells (Beachy et al., 2004) . Inappropriate activity of the Hh signaling pathway also has been linked to tumor types that arise sporadically or in genetically predisposed individuals (Varjosalo and Taipale, 2008; Yauch et al., 2008) .
Response to the Hh protein signal is governed by Patched (PTCH), a 12-pass transmembrane protein that restrains the activity of Smoothened (SMO), a member of the 7-transmembrane family of serpentine receptors ( Figure 1A ). Hh protein, when present (Taipale and Beachy, 2001) , binds PTCH and blocks its inhibition of SMO, thus permitting accumulation of SMO in the primary cilium (Corbit et al., 2005; Rohatgi et al., 2007) , and causing activation of the Gli family of transcription factors. Pathway activation via SMO thus can occur either by Hh protein stimulation or through loss of PTCH activity, as
Significance
The inappropriate activity of the Hh signaling pathway noted in a variety of tumor types has prompted efforts to develop small-molecule antagonists of Hh pathway signaling. Such drug development efforts, however, are costly and timeconsuming. With the identification of itraconazole, a commonly used systemic antifungal, as a potent inhibitor of the Hh pathway in vitro and in vivo, it may be possible to avoid some of the expense and delay associated with de novo development of Hh pathway antagonists. Supporting the rapid entry of itraconazole into clinical trials in the treatment of Hh-dependent cancers, serum levels that inhibit growth of tumors in mice are comparable to those reported in humans. seen in sporadic cancers or those that arise in the familial cancer predisposition syndrome, BCNS (basal cell nevus syndrome, associated with heterozygous mutation of the human PTCH gene).
Cyclopamine and other small molecules that antagonize Hh pathway activity (Chen et al., 2002a; Chen et al., 2002b; Cooper et al., 1998; Frank-Kamenetsky et al., 2002; Incardona et al., 1998; Taipale et al., 2000) have been found to act predominantly, although not exclusively, by binding the essential pathway component SMO. These small molecules have been effective in blocking Hh pathway-dependent growth of transformed cells, both in vitro (Taipale et al., 2000) and in vivo (Berman et al., 2002; Dierks et al., 2008; Romer et al., 2004; Yauch et al., 2008; Zhao et al., 2009) , thus stimulating major efforts to develop smallmolecule antagonists of the Hh pathway as cancer therapeutics. However, drug development is time-consuming and costly (DiMasi et al., 2003; Frank, 2003) , and we sought to circumvent this delay and expense by identifying Hh pathway antagonists among drugs that have been tested for toxicity in humans or even approved for human use by the US Food and Drug Administration (FDA).
RESULTS AND DISCUSSION
We screened a library of $2400 FDA-approved or post-phase I drugs (Chong et al., 2006a; Chong et al., 2006b ) (now part of the Johns Hopkins Clinical Compound Library) for activity in inhibition of Hh signaling. This screen made use of a reporter cell line, Shh-Light2 (Taipale et al., 2000) (see Experimental Procedures), which contains a stably integrated Gli-luciferase reporter that responds to stimulation by SHHN, the active form of the Sonic hedgehog (SHH) signaling protein.
Although several dozen hits were identified from preliminary screening, only a few were active in pathway inhibition at concentrations achieved in humans. Among these the microtubule inhibitors, including vinca alkaloids and their derivatives, consistently acted as Hh pathway antagonists (see Figure S1 available online). Their cytotoxic nature, however, precludes an extended and continuous course of treatment, as may be required for therapy of cancers by antagonism of Hh pathway activity (Berman et al., 2002; Romer et al., 2004; Yauch et al., 2008) . A more promising candidate, itraconazole, was identified as a potent inhibitor of Hh pathway activity with an IC 50 of approximately 800 nM ( Figure 1B ). This antifungal is commonly used in clinical practice as an orally delivered systemic treatment that can be sustained for months (Stevens, 2001) .
Itraconazole inhibits 14-a-lanosterol demethylase (14LDM), by a mechanism in which the triazole group of itraconazole coordinates the heme Fe 2+ in the cytochrome P-450 active site of 14LDM (Georgopapadakou and Walsh, 1996) . 14LDM is critical for the biosynthesis of ergosterol in fungi and cholesterol in mammals (Lepesheva and Waterman, 2007) (Figure 1C ). Itraconazole is significantly more potent in inhibiting the fungal enzyme (Lamb et al., 1999; Trosken et al., 2006) but has been shown to decrease human cholesterol levels at high doses (Schneider et al., 2007) .To test whether azole antifungals in general act to inhibit Hh pathway activity, we examined five other imidazole and triazole antifungal drugs. We found that itraconazole was by far the most potent inhibitor of Hh pathway activity, with an IC 50 more than 10-fold lower than that of ketoconazole, its nearest rival (IC 50 z9 mM; see Figure 1D and Table S1 ). Hydroxy-itraconazole, the major metabolite of itraconazole in humans, is equally potent in its antifungal activity (Harvey et al., 1980; Hostetler et al., 1993) , and also inhibited Hh pathway activity (IC 50 z1.2 mM; see Figure 1E ). Interestingly, fluconazole, an antifungal with similar potency for 14LDM as itraconazole (Lamb et al., 1999; Trosken et al., 2006) , shows no detectable inhibition of Hh pathway activity, even at a level 50-fold higher than the IC 50 of itraconazole. We thus conclude that azole antifungal drugs as a general class are not inhibitors of Hh pathway activity.
The inability of fluconazole to inhibit Hh pathway activity, despite a similar potency for inhibition of 14LDM as itraconazole, suggests that the effect of itraconazole is not due to an effect on cellular cholesterol biosynthesis. Curiously, however, we noted that increasing serum levels in our assays blocked pathway inhibition by itraconazole ( Figure 2A ). This blocking effect was absent in lipid-depleted serum ( Figure 2B ), suggesting that a factor removed by lipid depletion of serum can interfere with or reverse the action of itraconazole. A similar interfering effect of serum but not lipid-depleted serum was noted with pathway activation by the small-molecule agonist SAG (Chen et al., 2002b) (Figures S2A and S2B ).
To investigate this serum effect further, we directly tested the effects of cholesterol and its biosynthetic precursors lathosterol and desmosterol (see Figure 1C ). In cultured cell signaling assays, our laboratory has shown that statins can inhibit Hh signal response, but only if transient cyclodextrin pretreatment is first used to deplete cellular sterols (Cooper et al., 2003) ; itraconazole in contrast does not require cyclodextrin pretreatment to inhibit the Hh pathway. Furthermore, although the addition of cholesterol to cyclodextrin pretreated cultures in lipid-depleted serum reversed the inhibitory effects of statins on Hh response ( Figure 2C ) and cell proliferation ( Figures S2C-S2E ), the inhibitory effect of itraconazole was not reversed by supplementation of cultures with up to 25 mM lathosterol or desmosterol ( Figures  2D and 2E ) or 250 mM cholesterol as an ethanolic solution or in water-soluble form (Figures S2F and S2G) . These results further reinforce the conclusion that itraconazole inhibition of Hh response is not mediated through inhibitory effects on sterol biosynthesis.
We next considered whether specific lipoprotein particles in serum might account for the reversal of itraconazole action on the Hh pathway, and found that low-density lipoprotein (LDL) but not high-density lipoprotein or very low-density lipoprotein particles dramatically interfered with itraconazole action on Hh pathway activity ( Figures 3A-3C ). The megalin member of the LDL receptor family (Fisher and Howie, 2006; Hussain et al., 1999) has been shown to bind and endocytose SHH (McCarthy et al., 2002) , suggesting the possibility that LDL may interfere with itraconazole by affecting reception of the Hh signal. This is unlikely, however, because itraconazole acts below the level of the Hh receptor PTCH (see below); LDL furthermore interferes with itraconazole action even in cells lacking PTCH ( Figure 3D ). We thus conclude that the interfering effect of serum is not due to reversal of a sterol biosynthetic defect, nor through a LDLmediated effect on Hh reception, but more likely through sequestration of itraconazole by LDL lipoprotein particles, which have been shown to sequester and interfere with the action of other hydrophobic compounds such as benzo(a)pyrene (Remsen and Shireman, 1981; Shu and Nichols, 1979) and p-dimethylaminoazobenzene (Chen et al., 1979) .
We investigated the target of itraconazole action within the Hh pathway by examining cells with the Ptch gene disrupted by in frame fusion of lacZ (Goodrich et al., 1997; Taipale et al., 2000) . Loss of PTCH function in these cells causes constitutive pathway activity and consequent expression of b-galactosidase through activation of the Ptch promoter. Itraconazole treatment of these cells inhibited b-galactosidase expression at levels similar to those required for inhibition of pathway activity in SHHN-stimulated Shh-Light2 cells (IC 50 z900 nM; Figure 4A ). These results indicate that itraconazole acts independently of and downstream of PTCH. In contrast to Ptch À/À cells, the inhibitory action of itraconazole was bypassed by expression of SmoA1 (Taipale et al., 2000; Xie et al., 1998) , a constitutively active oncogenic variant of murine SMO ( Figure 4B ), suggesting that itraconazole does not act downstream of SMO. To define further the target of itraconazole action, we combined itraconazole treatment with pathway activation by overexpression of SMO or by treatment with the oxysterols 20(S)-and 22(S)-hydroxycholesterol (Corcoran and Scott, 2006; Dwyer et al., 2007) . We found that itraconazole blocked pathway activity produced by SMO overexpression ( Figure 4C ). Itraconazole also completely blocked oxysterol action (IC 50 z270 nM; Figure 4D ), suggesting that oxysterols act on a target distinct from and upstream of the target of itraconazole.
The ability to suppress pathway activity from SMO overexpression but not from SMOA1 suggests that itraconazole may act by binding to SMO as an inverse agonist (Bond et al., 1995; Costa and Herz, 1989) ; binding to SMO also could account for itraconazole effects in Ptch À/À cells, or in cells treated with oxysterols. Therefore, we also examined the effect of itraconazole treatment on localization of SMO, which has been shown to accumulate in the primary cilium upon Hh stimulation (Corbit et al., 2005; Rohatgi et al., 2007;  Figure 4E ). We found that itraconazole treatment dramatically reduced Shh-induced accumulation of SMO in the primary cilium ( Figure 4E ), similar to other SMO antagonists, SANT-1 and SANT-2, but in contrast to cyclopamine, which induced accumulation of SMO in the primary cilium (Rohatgi et al., 2009; Wang et al., 2009 ). The ability of itraconazole to suppress SHH-induced accumulation of SMO in the primary cilium is consistent with direct action of itraconazole on SMO for pathway inactivation.
Like itraconazole, cyclopamine inhibits pathway activity in Ptch À/À cells (Taipale et al., 2000) , in cells treated with oxysterols (Dwyer et al., 2007) , and in cells overexpressing SMO (Taipale et al., 2000) , but not in SMOA1-expressing cells (Taipale et al., 2000) . As proposed above for itraconazole, cyclopamine and many other antagonists act by binding to SMO (Chen et al., 2002a; Chen et al., 2002b; Frank-Kamenetsky et al., 2002) . We therefore tested itraconazole for SMO binding using BODIPY-cyclopamine, a fluorescent cyclopamine derivative, and a cell line that expresses SMO upon induction by treatment with tetracycline (Dwyer et al., 2007) . We found that BODIPY-cyclopamine binding to SMO was not affected significantly by itraconazole, even at 10 mM, a concentration 12.5-fold higher than its IC 50 ( Figure 5A ). This contrasts sharply with the potent cyclopamine derivative, KAAD-cyclopamine (IC 50 = 20 nM), which reduced bound BOD-IPY-cyclopamine to near-background levels at 200 nM ( Figure 5A ). Although itraconazole fails to compete with BODIPY-cyclopamine, it could nevertheless bind SMO at a distinct site from cyclopamine. If so, itraconazole conceivably could bind simultaneously with cyclopamine or with other small molecule agonists and antagonists that bind at the cyclopamine site. Itraconazole thus may synergize with cyclopamine or other SMO antagonists in pathway inhibition and it may act noncompetitively with SMO agonists that bind at the cyclopamine site. Indeed, we found that the IC 50 of KAAD-cyclopamine decreased from 20 nM to 2 nM with increasing doses of itraconazole ( Figure 5B and Table S2 ), and that the IC 50 of itraconazole decreases from 800 nM to 130 nM with increasing doses of KAAD-cyclopamine ( Figure 5C and Table  S3 ). In addition, the maximal degree of pathway activation by SAG, whose SMO binding site overlaps that of cyclopamine, was reduced by increasing concentrations of itraconazole without altering the SAG EC 50 ( Figure 5D and Table S4 ), indicating that itraconazole acts as a non-competitive inhibitor (Taylor and Insel, 1990) . Itraconazole, in summary, behaves like an inverse agonist, suppresses the accumulation of SMO in the primary cilium, mutually enhances the potency of pathway inhibition in combination with cyclopamine, and acts as a noncompetitive inhibitor of pathway activation by SAG. These characteristics of itraconazole are consistent with the binding of itraconazole to SMO at a distinct site from that of cyclopamine. Given that we have not demonstrated direct binding of itraconazole to SMO, the possibility remains that itraconazole may exert its inhibitory action on SMO through other indirect mechanisms.
Having characterized the Hh pathway inhibitory activity of itraconazole in vitro, we examined its effect in vivo by systemic treatment of animals subcutaneously engrafted with a primary medulloblastoma from a Ptch +/À ; p53 À/À mouse. Medulloblastomas from these mice depend on constitutive Hh pathway activity for their growth (Berman et al., 2002; Goodrich et al., 1997; Romer et al., 2004) and this growth can be inhibited by pathway antagonists (Berman et al., 2002; Romer et al., 2004) . Treatment with itraconazole indeed inhibited growth of these subcutaneous allografts, with similar inhibition of tumor growth noted for animals treated with itraconazole at 100 mg/kg twice per day (b.i.d.) or 75 mg/kg b.i.d. (Figure 6A ). Consistent with the synergistic effect of itraconazole and cyclopamine in vitro, combined treatment with itraconazole and cyclopamine produced an even greater inhibition of tumor growth. Mice bearing control tumors were euthanized after 18 days as the tumors exceeded the size limits set forth by our Institutional Animal Care and Use Committee. At the end of the experiment, 4 hr after the last dose, we obtained serum and tumors from three mice in each treatment group. Itraconazole concentrations were measured using a bioassay method based on antifungal activity (Hostetler et al., 1992; Rex et al., 1991) that does not distinguish between itraconazole and hydroxy-itraconazole (Hostetler et al., 1993) . Itraconazole concentrations reported here therefore represent a combined measurement of itraconazole and hydroxy-itraconazole effects. Serum itraconazole concentrations were similar between the 100 mg/kg and 75 mg/kg groups ( Figure 6B ). Itraconazole levels achieved in tumors ( Figure 6C ) were similar to drug levels in serum, indicating that itraconazole has good tumor tissue penetration. The area-under-the curve (AUC) values for serum concentrations of itraconazole reached during a 24 hr pharmacokinetic study ( Figure 6D ) were also similar for itraconazole given at 100 mg/kg and 75 mg/kg (220 mg $ hr/ml and 238 mg $ hr/ml, respectively). These findings are consistent with previously published pharmacokinetic results (Hostetler et al., 1992) .
We also tested the ability of itraconazole to inhibit pathway activity in tumor tissue in a separate experiment that made use of mice bearing secondary subcutaneous medulloblastoma allografts from the same original tumor as that used for studies of tumor growth (see above). These mice were treated either with 100 mg/kg itraconazole b.i.d. or 37.5 mg/kg cyclopamine b.i.d. The treated tumors showed decreased Gli1 mRNA levels, indicative of reduced Hh pathway activity as compared with cyclodextrin vehicle-treated controls ( Figure 6E ). To further assess the activity of itraconazole on suppression of Hh-dependent tumors, we used K14-CreER; Ptch +/À ; p53 fl/fl mice to generate endogenous basal cell carcinomas (BCC) of the skin (see Experimental Procedures). BCC tumors generated from these mice have increased levels of Hh pathway activity and their growth is suppressed by Hh pathway inhibitors (Xiao et al., 2009) . Itraconazole treatment suppressed the growth of the endogenous BCC tumors when compared with the cyclodextrin vehicle control ( Figure 7A ). When itraconazole was stopped after 18 days of treatment ( Figure 7A ), the tumors began to grow again at a rate similar to that of vehicle-treated control tumors. At the end of the study, tumors from itraconazoletreated mice appeared to have greater levels of necrosis as compared with tumors from vehicle-treated mice, based on destruction of basophilic tumor cell nests and the eosinophilic stroma surrounding these nests ( Figure 7B ). Tabulation of necrosis scores, with a higher score indicating worse necrosis, confirmed that histologically assessed necrosis was greater for itraconazole-treated BCC as compared with vehicle-treated tumors ( Figure 7C ).
The serum concentrations of itraconazole associated with an antitumor effect in our in vivo studies are higher than those reached in humans at regular therapeutic doses (Barone et al., 1993 ) (i.e., 400 mg/day orally for 15 days). Similar high serum levels of itraconazole (Sanchez et al., 1995) , however, have been reported in patients treated for severe fungal infections. This high-dose itraconazole therapy has ranged from 600 to 900 mg/day (Sanchez et al., 1995; Sharkey et al., 1991; Takagi et al., 2001 ) over treatment periods ranging from 3 to 16 months, with occasional toxicities that were manageable (Sharkey et al., 1991) . It is of interest that ketoconazole, another azole antifungal, has been used as second-line therapy for androgen-independent metastatic prostate cancer (Scholz et al., 2005; Trump et al., 1989) at doses 3-to 6-fold higher than its normal dose and with toxicities greater than those for high-dose itraconazole (Sugar et al., 1987) . The use of ketoconazole in this context is believed to act by inhibiting androgen production, but we cannot rule out the possibility of an effect on Hh pathway activity.
Hh pathway activity has been characterized as contributing to growth of many tumor types (Varjosalo and Taipale, 2008; Yauch et al., 2008) . Recent studies in the mouse have shown that another cancer, chronic myelogenous leukemia (CML), is dependent on Hh signaling. SMO activity is necessary for maintenance of CML stem cells and mouse and human CML that becomes resistant to tyrosine kinase inhibitor therapy remains sensitive to manipulation of SMO activity (Dierks et al., 2008; Zhao et al., 2009) .
The importance of the Hh pathway in tumor growth has led to an active interest in the development of small-molecule Hh pathway antagonists (Tremblay et al., 2009 ). Most of these molecules are either cyclopamine derivatives or they antagonize pathway by binding SMO at the same site as cyclopamine. Recent clinical tests of one of these cyclopamine mimics, GDC-0449 Von Hoff et al., 2009) , produced promising results, suggesting that Hh pathway inhibition may represent an effective approach to cancer therapy. Further Table S3 ). (D) KAAD-cyclopamine is a competitive inhibitor of SAG, a known Hh pathway agonist, as shown by shifts of the SAG EC 50 by $5 and $13 fold at 40 nM and 100 nM concentrations of KAAD-cyclopamine. In contrast, itraconazole did not alter the SAG EC 50 but decreased the maximal activity of SAG, thus acting as a noncompetitive inhibitor (see Table S4 ). All signaling assays were performed with Shh-Light2 cells in 0.5% serum media and data represent mean of triplicates ± SD. See also Tables S2, S3, and S4. clinical testing will be required to establish efficacy and longterm safety of such agents (Dlugosz and Talpaz, 2009) .
Itraconazole has been studied for nearly 25 years, and we therefore have a good understanding of its safety and potential side effects. Furthermore, itraconazole is already used in human patients at doses that produce serum concentrations like those found to be effective in our murine medulloblastoma and BCC models. It is worth noting that itraconazole acts at a distinct site from cyclopamine; itraconazole and related compounds may therefore represent a helpful adjunct or alternative to the cyclopamine mimics currently under widespread development. For these reasons, particularly its well-known safety profile, it should be possible to quickly evaluate itraconazole either alone or in combination with other targeted therapies or cytotoxic agents in patients with tumors of known Hedgehog pathway dependence. Treatments were given twice per day by oral gavage. The number of tumors used in this experiment were: Cyclodextrin control n = 8, itraconazole 100 mg/kg n = 12, itraconazole 75 mg/kg n = 10, cyclopamine 37.5 mg/kg n = 10, itraconazole/cyclopamine n = 10. Data are expressed as mean percentage change in volume ± standard error of the mean (SEM). (B and C) Mean serum and tumor itraconazole levels obtained at the end of the allograft study in (A) are shown in panels (B) and (C), respectively. The dashed lines represent the minimum detectable levels of the assay; vehicle controls were at or below these levels. (D) Pharmacokinetics of itraconazole levels in serum of athymic nude mice after one oral dose of itraconazole 100 mg/kg or 75 mg/kg. All itraconazole levels were obtained using the bioassay method (Clemons et al., 2002; Harvey et al., 1980; Hostetler et al., 1992; Rex et al., 1991) . Data for itraconazole levels in (B)-(D) represent the mean of three samples ± SD. (E) Hh pathway is decreased in allografted medulloblastoma tumors when treated with either itraconazole or cyclopamine as compared to cyclodextrin control treatment. Hh pathway was monitored by Gli1 mRNA levels. Gli1 mRNA levels of drug treatments were normalized to the mean of Gli1 mRNA levels of cyclodextrin control. Treatments were given twice per day for 4 days by oral gavage. **p = 0.0197; ***p = 0.0386.
EXPERIMENTAL PROCEDURES
Cell Culture Assays for Hh Pathway Activation Shh-Light2 cell line (Taipale et al., 2000) is a clonal NIH 3T3 cell line stably transfected with 83-Gli1-binding site dependent firefly luciferase and Renilla luciferase reporters. SmoA1 Light cell line is a clonal subline of Shh-Light cells stably transfected with oncogenic SmoA1 (Taipale et al., 2000) . Shh-Light2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) calf serum, penicillin, streptomycin, L-glutamine supplemented with Geneticin (Invitrogen) 400 mg/ml, and Zeocin (Invitrogen) 100 mg/ml. SmoA1-Light cells were maintained in DMEM containing 10%(v/v) calf serum, penicillin, streptomycin, L-glutamine supplemented with Geneticin 400 mg/ml and Hygromycin (CalBiochem) 100 mg/ml. Ptch À/À MEF cell line (Taipale et al., 2000) was maintained in DMEM containing 10% fetal bovine serum, penicillin, streptomycin, L-glutamine supplemented with Geneticin 400 mg/ml. SHHN conditioned medium (CM) was prepared as previously described (Maity et al., 2005) . HEK293 CM was used for control. HEK293 CM was prepared in the same manner as SHHN CM. Stock SHHN CM and HEK293 CM (for control) were diluted 10-fold with the appropriate media for various Hh pathway signaling assays.
For SMO overexpression assay in NIH 3T3 cells, Smo, GFP, Gli-dependent firefly luciferase reporter, and TK-Renilla luciferase reporter vectors have been described previously (Taipale et al., 2000) . Fugene 6 (Roche Applied Science) was used for transient transfection of the vectors at a ratio of 4 ml:1.5 mg (Fugene6:DNA). Each well of a 24 well multiwell plate was transfected with 375 ng total DNA. Signaling assay for Ptch À/À cells was performed similarly except for Fugene:DNA ratio of 3 ml:10 mg with 250 ng total DNA per well of a 24-well plate. All assays for Hh pathway activation were performed in 24 well tissue culture plates. Cells were grown in 10% (v/v) serum media until completely confluent. Drugs, 293 CM, and SHHN CM were diluted in DMEM containing 0.5% (v/v) serum unless otherwise noted in main text and figure legends. Cells were incubated for 40-46 hr with drug treatments, except for the comparison of various azole (30 hr) and SMOA1 (30 hr) to minimize toxicity from the high concentrations of azole antifungals and forskolin, respectively. After internal normalization of firefly luciferase with tk-Renilla luciferase for each well, relative luciferase units were obtained by normalization of Hh pathway stimulated cells with unstimulated cells (all other conditions being equal) grown on a separate plate in parallel. All luminescence assays were performed on a Fluostar Optima (BMG Labtech). Luminescence assays were performed according to manufacturer's instructions using Dual Luciferase Assay Reporter System (Promega). b-Galactosidase activity of Ptch À/À cells were obtained with 
Fluorescent BOPDIPY-Cyclopamine Competition Assays
Maintenance and induction of SMO in the HEK293S cell line stably expressing a tetracycline inducible Smo gene has been described previously (Dwyer et al., 2007) . After 2 days of SMO induction, cells were incubated with BODIPY-cyclopamine 10 nM ± inhibitors at 37 C for 4-6 hr. Cells were trypsinized, washed with phosphate-buffered saline (PBS) after centrifugation, pelleted by centrifugation and resuspended in 0.5% calf serum/phenol red-free DMEM. BODIPY fluorescence was measured on FACSAria (Becton Dickinson). Fluorescence-activated cell sorting data were analyzed with FlowJo software.
Immunofluorescence NIH 3T3 cells were grown to confluence on tissue culture treated glass coverslips (Fisher) and treated with various conditions for 6 hr as described previously for Hh pathway signaling assays. At the end of the incubation period, samples were fixed in methanol at À20 C and subsequently stained with appropriate antibodies. The antibodies used were as follows: rabbit polyclonal anti-SMO 1:750 dilution, mouse monoclonal anti-acetylated tubulin 1:1000 dilution (Sigma), AlexaFluor 488 goat anti-rabbit 1:667 dilution (Invitrogen), and AlexaFluor 594 goat anti-mouse 1:667 dilution (Invitrogen). Details of anti-SMO antibody have been described elsewhere ).
Translational Neuroscience. Maximum intensity overlay images of Z-stacks were obtained with Zeiss Zen software. Cilia from these images were quantified manually. For presentation of images, representative 300 3 300 pixel portions of each metafile were cut and maximum intensity overlay images of Z-stack were produced using Zeiss Zen software. The cut images were enlarged using Adobe Photoshop software. For inset images, portions were cut and enlarged using Adobe Photoshop. Subsequently, red and green channels were offset using ImageJ software. All images were then recombined and brightened equally using Adobe Photoshop.
In Vivo Drug Treatment Studies
All mouse studies were approved by and conformed to the policies and regulations of the respective Institutional Animal Care and Use Committees at Stanford University and the Children's Hospital Oakland Research Institute. (Martin, 1999) . For the itraconazole 75 mg/kg arm, oral itraconazole solution was diluted to 7.5 mg/ml with sterile water. Cyclopamine was dissolved in 10% (w/v) HPCD/0.1 M sodium citrate/ phosphate solution (pH 3) (Feldmann et al., 2007) at a concentration of 3.75 mg/ml. For itraconazole 100 mg/kg-cyclopamine 25 mg/kg, cyclopamine powder was dissolved in oral itraconazole 10 mg/ml solution to a final concentration of 2.5 mg/ml. A one-way analysis of variance was used for comparing all treatment arms with GraphPad Prism software.
Study of Medulloblastoma Tumor Growth Inhibition

Study of Treatment for Hh Pathway Inhibition
An untreated primary medulloblastoma allograft from the tumor growth study was minced, digested into a single cell suspension with collagenase IV (Worthington Biochemical), and stored in liquid nitrogen. Medulloblastoma cells were thawed and incubated overnight in defined serum-free media (Kalani et al., 2008) containing B-27 supplement without vitamin A(Invitrogen), mouse EGF 20 ng/ml (Peprotech), mouse bFGF 20 ng/ml (Invitrogen), minimal nonessential amino acids (Invitrogen), N-acetyl cysteine 60 mg/ml, Glutamax (Invitrogen) in Neurobasal A medium (Invitrogen). Cells were pelleted, washed with PBS, and mixed in 1:1 solution of PBS:growth-factor-reduced Matrigel as noted above. Approximately 1.2 million cells were injected into the flank of nude mice as noted above. Tumors were established and mice were treated twice per day by oral gavage for 4 days. Drugs were prepared as noted above.
Generation of Endogenous Basal Cell Carcinoma
Different mice carrying the K14-Cre-ER transgene (Metzger et al., 2005) , the floxed p53 allele (Jonkers et al., 2001) , and the Ptch1 +/À (Goodrich et al., 1997) alleles were bred together for generating Ptch1 +/À ; K14-Cre-ER; p53fl/fl mice. We treated these mice at age 6 weeks with 100 mg/day tamoxifen administered intraperitoneally for three consecutive days. At 8 weeks of age, Ptch1 +/À K14-Cre-ER p53fl/fl mice were exposed to 4 Gy of ionizing radiation (IR). Mice develop visible BCC tumors at 6 months of age.
Study of BCC Tumor Growth Inhibition
Four mice with a total of 20 visible BCC tumors were gavaged twice daily with oral itraconazole solution (Ortho-Biotec) 100 mg/kg, for 18 days. Itraconazole was discontinued on day 19, two mice were euthanized on day 19 and the tumors dissected for further examination and BCC tumors of the two remaining were followed until 22 days. Two mice with 10 BCC tumors were treated with 40% w/v HPCD (Sigma) for an average of 22 days at which point the mice were euthanized because of their large tumor size that exceeded our animal care guidelines. We measured the change in the long axis of BCC tumor size with calipers every 3 days (So et al., 2004) . Pairwise comparisons between cyclodextrin control and itraconazole treatment arms were done using a two-sided unpaired t test with GraphPad Prism software.
Necrosis Scoring of BCC Tumors
Hematoxylin and eosin stained (H&E) sections of paraffin-embedded BCC tumors after the growth inhibition study were examined for necrosis. Necrosis was scored as follows: 0 = no evidence of necrosis with large basaloid cells; 1 = mild necrosis with nuclear pyknosis; 2 = moderate necrosis with < 25% necrosis; 3 = severe necrosis with > 25% necrosis. After tabulation of necrosis scores, pairwise comparison between cyclodextrin control and itraconazole treatment tumors were made using a two-sided unpaired t test with GraphPad Prism software.
Itraconazole Levels
For the itraconazole pharmacokinetic study, 7-to 8-week-old female outbred athymic nude mice were given one dose of itraconazole 100 mg/kg or 75 mg/ kg or equivolume of 40% HPCD solution at time = 0 hr point. At each time point, three mice from each treatment arm were anesthetized, exsanguinated, blood collected, and euthanized. Blood was allowed to clot and the resultant serum used for bioassays to measure itraconazole levels. Serum from untreated athymic nude mice was used for obtaining the standard curve for the bioassays. Area under the curve (AUC) from 0-24 hr were calculated with GraphPad Prism software with the trapezoidal rule method. For itraconazole concentrations from the medulloblastoma allograft study, serum from three mice of each treatment and control arm were obtained at the end of the study in a similar manner to the pharmacokinetic study.
For itraconazole concentrations of tumors from the medulloblastoma allograft study, mice were exsanguinated under isoflurane anesthesia and perfused with PBS via the left ventricle to remove any blood that might confound tumor itraconazole levels. Tumors were excised and frozen on dry ice, ground, and extracted with solvent for drug assay as previously described (Clemons et al., 2002) . Serum and tissue antifungal itraconazole concentrations were determined by bioassay method, with itraconazole standards, as described elsewhere (Clemons et al., 2002; Harvey et al., 1980; Hostetler et al., 1992; Rex et al., 1991) .
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